Nattawat Klomjit

Someone who love kidneys and physiology😷| He, him, his.

[Nattawat Klomjit @basmeomeo]

Honored to received an KI-ISN early career research award and excited to attend WCN in Yokohama, Japan this March. Thanks 🙏 @LadanZand @UMNews @ISNkidneycare

[Int Society of Nephrology @ISNkidneycare]

@vjha126 @kellumja @RonGansevoort @simonfleclerc @YokoShirai_twmu @GovindDrsuk @ogokoye2020 @drpriyapais @HudaAkrabi @jsnorjp 𝗞𝗜-𝗜𝗦𝗡 𝗘𝗮𝗿𝗹𝘆 𝗖𝗮𝗿𝗲𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿 𝗔𝘄𝗮𝗿𝗱𝘀:
𝗕𝗮𝘀𝗶𝗰 𝗦𝗰𝗶𝗲𝗻𝗰𝗲:
🇵🇹 Sara Patricia Monteiro-Martins
🇨🇳 Shuai-shuai Xie

𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲:
🇨🇦 Ping Liu
🇺🇸 @basmeomeo
#ISNWCN

[Nattawat Klomjit @basmeomeo]

@HanzMadC @deniise_am @LadanZand @UMNews @onconephsociety @ISNkidneycare Thank you 😊

[Nattawat Klomjit @basmeomeo]

Grateful and honored to be the recipient of KI-ISN early career research award 🥇 2026. See you in Japan 🇯🇵. @LadanZand @UMNews @onconephsociety @ISNkidneycare

[Nattawat Klomjit @basmeomeo]

@myadla @LadanZand @UMNews @onconephsociety @ISNkidneycare Thank you !!

[Nattawat Klomjit @basmeomeo]

@rc_oncneph @LadanZand @UMNews @onconephsociety @ISNkidneycare Thanks Raad 😇

[Nattawat Klomjit @basmeomeo]

@anuja_java @LadanZand @UMNews @onconephsociety @ISNkidneycare Thanks Anuja :). Hope to see you in Japan 😇

[Nattawat Klomjit @basmeomeo]

@LoriBaker444 @LadanZand @UMNews @onconephsociety @ISNkidneycare Thanks Lori 😇

[Nattawat Klomjit @basmeomeo]

@SwethaKanduriMD @LadanZand @UMNews @onconephsociety @ISNkidneycare Thanks Swetha! Will you be in Japan!?

[Nattawat Klomjit @basmeomeo]

@JohannMorelle @LadanZand @UMNews @onconephsociety @ISNkidneycare Thanks Johann! Will u be in Japan for WCN?

[Nattawat Klomjit @basmeomeo]

@AbdullahJalalMD @LadanZand @UMNews @onconephsociety @ISNkidneycare Thanks! Abdullah !

[Nattawat Klomjit @basmeomeo]

Glad to be part of the USTMA :) @anuja_java and great collaboration.

[Anuja Java, MD (she/her) @anuja_java]

USTMA Wrapped 2025 🎉🎉🎉

A year powered by collaboration, community & shared purpose!!

We are deeply grateful to our patients, families, clinicians, researchers & advocates who showed what’s possible when a community comes together 🙏🙏

https://t.co/gxaM0SCzxi

[Nattawat Klomjit @basmeomeo]

Double trouble for membranous nephropathy! Dual-Ag MN have been reported: some co exist with PLA2R1. Nearly 90% of cases have hematuria. Further questions remain: how do these patients differ clinically in terms of clinical characteristics, severity or outcomes? @ASNKidney

[Nattawat Klomjit @basmeomeo]

Key take away from Dr. Nasr’ s talk about Cryo GN (one of my fav MGRS).
- Type 2 Cryo is the most common type, HCV being the most common.
- Non-HCV type 2 cryo, still has sizable association with lymphoproliferative d/o>> so attempt to rule this out is suggested ✅🩸 #KidneyWk

[Nattawat Klomjit @basmeomeo]

@kidneymo @ASNKidney @GlomCon @onconephsociety @CleClinicKidney Glad to have met you! Safe trip home.

[Nattawat Klomjit @basmeomeo]

@SwethaKanduriMD @ASNKidney @onconephsociety @wisit661 @onconeph @HerrmannMd @ShrutiGkidney Great to meet u! Safe trip back home.

[Nattawat Klomjit @basmeomeo]

Another positive Phase 3 trial of Hit 1 targeted therapy. Awaiting to hear the FDA decision about drug approval by this December so stay tuned. #KidneyWk #IgAN

[NEJM @NEJM]

Presented at #KidneyWk:

In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. Full VISIONARY phase 3 trial results: https://t.co/zSyiaVVPlQ

@ASNKidney

[Nattawat Klomjit @basmeomeo]

Great talk by Dr. Falk re: Longterm remission of therapy (LTROT) in ANCA asso GN. Ultimate goal that we should aim for.
-1/3 of ANCA pt achieved this
-risk of relapse decreases with time(10-15% first 1-2 years, 1-2%/yr post 2 y). #KidneyWk

[Nattawat Klomjit @basmeomeo]

Proudly present 🎁 a case of histiocytic glomerulopathy 2/2 vasculitis, without HLH. #KidneyWk #ASN2025

[Nattawat Klomjit @basmeomeo]

Thank you 🙏 for all who visit our poster today 😇 Hypomagnesemia..an overlooking electrolytes. #KidneyWk #ASN2025 @onconephsociety

[Nattawat Klomjit @basmeomeo]

Atacicept, double BAFF and APRIL blockade, has shown promising result and met primary endpoint for UPCR reduction at 36 weeks in ORIGIN 3. Excited for the 2 years data of eGFR slope in a couple years. In 5 years, we perhaps have at least 10 FDA approved drugs for IgAN. #KidneyWk